We are monitoring the impact of COVID-19 on Latin America Cancer Vaccines Market Get in touch with us for detailed analysis Know More
Share on

Latin America Cancer Vaccines Market Research Report – Segmented By Treatment Type, Cancer Type, Vaccine Type, End User & Country (Brazil, Argentina, Chile, Mexico and Rest of Latin America) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1347
Pages: 145

Latin American Cancer Vaccines Market Size (2022 to 2027)

The size of the Latin American Cancer Vaccines Market was worth USD 0.55 billion in 2022 and estimated to reach USD 1.24 billion by the end of 2027, hiking at a CAGR of 17.52% between 2022 to 2027.

Cancer vaccines are biological response modifiers. The fact that these biological response modifiers work by activating the body's immune system to combat cancer is a crucial element driving the growth of the Latin American cancer vaccines market. In addition, an increase in the number of cancer patients, a rise in the geriatric population, a rise in patient awareness of cancer therapy, an increase in the use of cancer vaccines in combination with other therapies, and an increase in the prevalence of human papillomavirus (HPV) infections are driving the cancer vaccines market forward in Latin American region.

The expansion of the cancer vaccines market is fuelled by manufacturers' increased investments and government funding to develop cancer vaccines. Furthermore, rising cigarette smoking and unhealthy dietary habits are key risk factors for increasing cancer cases, accelerating the market for cancer vaccines in this region.

Other factors contributing to the expansion of the Latin American cancer vaccines market include technological advancements in cancer vaccines, the launch of innovative cancer vaccines, an increase in health care services and expenditures, and an increase in the acceptance rates of preventative and therapeutic vaccines.

The high expense of creating cancer vaccines and the longer time it takes to make a single vaccination are expected to limit the growth of the Latin American cancer vaccines market. In addition, the market's expansion is hampered by strict regulatory rules and the presence of alternative therapists. During the projection period, the cost of gene therapy treatment, undesired immune reactions, and the risk associated with the treatment are projected to stifle market expansion. On the other hand, an increasing global geriatric population, favorable reimbursement policies, technological improvements, and untapped market prospects given by emerging economies are likely to produce profitable opportunities for market players.

This research report on the Latin American cancer vaccines market has been segmented and sub-segmented into the following categories.

By Cancer Type:

  • Prostate
  • Cervical
  • Colorectal
  • Throat
  • Others

By Vaccine Type:

  • Protein
  • Peptide-based
  • Tumor cell
  • Dendritic cell
  • Genetic vaccines
  • Others

By End User:

  • Cancer Treatment Centres
  • Research Institutes

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Latin America had a moderate share of the global cancer vaccines market in 2020. Mexico, Brazil, and Argentina have more excellent healthcare infrastructure than most of the region's developed countries. According to the National Cancer Institute (NCI), national cancer spending exceeds USD 156 billion by 2020. However, there are a limited number of vaccines on the market because the cancer vaccine market is still in its infancy. The market is being driven by factors such as rising cancer incidence, a lack of effective treatments, and the need to lessen the region burden of cancer. In 2012, the World Health Organization reported 14.2 million cancer cases and 8.2 million cancer deaths. The most common cancers were lung, colorectal, prostate, cervical, and breast cancers. As a result, vaccines to prevent and treat cancer are in high demand.

The Brazilian market is forecasted to play a leading role in the Latin American market during the forecast period due to the growing geriatric population, well-established healthcare infrastructure and specialized medical practitioners, advanced technological developments, presence of major manufacturers, and high adoption of cancer gene therapy treatment.

During the forecast period, the Mexican market is also expected to expand at a healthy CAGR. In addition, consumer awareness of cancer gene therapy is growing due to increased government activities and advances in healthcare infrastructure.

KEY MARKET PLAYERS:

Dendreon, GlaxoSmithKline, and Merck are companies that dominate the Latin American cancer vaccines market. In addition, companies with their products in the pipeline are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian  Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx,  OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology Data                   

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Treatment type                        

                                5.1.1 Prophylactic           

                                5.1.2 Therapeutic            

                                5.1.3 Y-o-Y Growth Analysis, By Cancer Type       

                                5.1.4 Market Attractiveness Analysis, By Cancer type      

                                5.1.5 Market Share Analysis, By Cancer Type       

                5.2 Cancer Type               

                                5.2.1 Introduction           

                                5.2.2 Prostate Cancer    

                                5.2.3 Cervical Cancer     

                                5.2.4 Colorectal Cancer 

                                5.2.5 Throat Cancer        

                                5.2.6 Others      

                                5.2.7 Y-o-Y Growth Analysis, By Cancer Type       

                                5.2.8 Market Attractiveness Analysis, By Cancer type      

                                5.2.9 Market Share Analysis, By Cancer Type       

                5.3 Vaccine Type                             

                                5.3.1 Introduction           

                                5.3.2 Tumour cell Vaccines          

                                5.3.3 Protein or Peptide Vaccines            

                                5.3.4 Genetic Vaccines  

                                                5.3.4.1 DNA Vaccines

                                                5.3.4.2 RNA Vaccines

                                5.3.5 Dendritic cell Vaccines       

                                5.3.6 other Vaccines      

                                5.3.7 Y-o-Y Growth Analysis, By Vaccine Type     

                                5.3.8 Market Attractiveness Analysis, By Vaccine Type    

                                5.3.9 Market Share Analysis, By Vaccine Type     

                5.4 End Users                   

                                5.4.1 Introduction           

                                5.4.2 Cancer Treatment Centers

                                5.4.3 Research Institutes             

                                5.4.4 Y-o-Y Growth Analysis, By End User              

                                5.4.5 Market Attractiveness Analysis, By End User            

                                5.4.6 Market Share Analysis, By End User             

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment Type

                                                6.1.3.3 By Cancer Type

                                                6.1.3.4 By Vaccine Type

                                                6.1.3.5 By End User

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment Type

                                                6.1.4.3 By Cancer Type

                                                6.1.4.4 By Vaccine Type

                                                6.1.4.5 By End User

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment Type

                                                6.1.5.3 By Cancer Type

                                                6.1.5.4 By Vaccine Type

                                                6.1.5.5 By End User

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Merck & co                 

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Dendreon                   

                8.3 Glaxosmithkline                       

                8.4 AstraZeneca plc                        

                8.5 Aduro BioTech                          

                8.6 MedImmune                             

                8.7 Sanofi                           

                8.8 Galena Biopharma                   

                8.9 Ubivac                          

                8.10 Oxford Biomedica                 

                8.11 Immunofrontier Inc                              

                8.12 Oncovir Inc                               

                8.13 Immune Cell Therapy (ICT)                

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Cancer Vaccines Market, By Treatment Type, From 2022 - 2027 (USD Million)
  2. Latin America Prophylactic Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  3. Latin America Therapeutic Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  4. Latin America Cancer Vaccines Market, By Cancer Type, From 2022 - 2027 (USD Million)
  5. Latin America Prostate Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  6. Latin America Cervical Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  7. Latin America Colorectal Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  8. Latin America Throat Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  9. Latin America Cancer Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Million)
  10. Latin America Tumour cell Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  11. Latin America Protein or Peptide Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  12. Latin America Genetic Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  13. Latin America Dendritic cell Vaccines Market, By Region, From 2022 - 2027 (USD Million)
  14. Latin America Cancer Vaccines Market, By End User , From 2022 - 2027 (USD Million)
  15. Latin America Cancer Treatment Centers' Vaccine Usage Market, By Region, From 2022 - 2027 (USD Million)
  16. Latin America Research Institutes' Vaccine Usage Market, By Region, From 2022 - 2027 (USD Million)
  17. Brazil Cancer Vaccines Market, By Treatment Type, From 2022 - 2027 (USD Million)
  18. Brazil Cancer Vaccines Market, By Cancer Type, From 2022 - 2027 (USD Million)
  19. Brazil Cancer Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Million)
  20. Brazil Cancer Vaccines Market, By End User , From 2022 - 2027 (USD Million)
  21. Argentina Cancer Vaccines Market, By Treatment Type, From 2022 - 2027 (USD Million)
  22. Argentina Cancer Vaccines Market, By Cancer Type, From 2022 - 2027 (USD Million)
  23. Argentina Cancer Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Million)
  24. Argentina Cancer Vaccines Market, By End User , From 2022 - 2027 (USD Million)
  25. Mexico Cancer Vaccines Market, By Treatment Type, From 2022 - 2027 (USD Million)
  26. Mexico Cancer Vaccines Market, By Cancer Type, From 2022 - 2027 (USD Million)
  27. Mexico Cancer Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Million)
  28. Mexico Cancer Vaccines Market, By End User , From 2022 - 2027 (USD Million)
  29. Rest of Latin America Cancer Vaccines Market, By Treatment Type, From 2022 - 2027 (USD Million)
  30. Rest of Latin America Cancer Vaccines Market, By Cancer Type, From 2022 - 2027 (USD Million)
  31. Rest of Latin America Cancer Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Million)
  32. Rest of Latin America Cancer Vaccines Market, By End User , From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample